Key oncology conferences like ASCO, ASH, and ESMO drive investment-informing clinical research, with recent ESMO 2024 data highlighting significant advancements in immunotherapy. Merck's ...

Jazz’s Global Head of R&D Robert Iannone, M.D., told Fierce Biotech ahead of ESMO that today’s updated results “reaffirm zanidatamab’s potential as a foundational treatment for patients ...

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – showed that nearly two-thirds (61.6%) of patients with brain metastases ...

Lantheus may have been hoping that “statistically significant” phase 3 data for its radioligand therapy would make a splash at ESMO, but not everyone is impressed. The biotech used the ...

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.

BARCELONA, Spain — Ten years ago, a new type of cancer treatment reached the market. It worked by rousing the body’s own immune cells to attack tumors. Within months, regulators had approved ...

Taking to the stage for the 2024 European Society for Medical Oncology (ESMO) Meeting in Barcelona, Spain, Exact Sciences said the study sought to simulate the screening population to predict the ...

At the European Society of Medical Oncology (ESMO) Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu (trastuzumab ...

These data are being presented today at the 2024 European Society for Medical Oncology Congress (ESMO 2024) during the Proffered Paper Session: GU Tumours, Prostate at 2:45 p.m. CEST. “Despite recent ...

“Our data at ESMO this year highlight BMS’ enduring impact in oncology and offer insights into our earlier-phase, next-generation assets,” said Samit Hirawat, M.D., executive vice ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert ...